Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 261 - 280 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financials; Looking Ahead to FT500 and FT516 Data Later This Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Platform, Limited Catalysts. Initiating at Neutral. $20 PT.
Provider: Roth Capital Partners, Inc.
Price: 75.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FATE Moving Fast with FT500, Data Likely by YE19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - AACR Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 75.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Terminating coverage due to reallocation of resources.
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports 4Q18 Results; Off-the-Shelf Program Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential of Engineered NK Cells: Putting a Value on Fate?s 500 Series
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 50.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2018: Key Presentations Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 75.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Presents Phase 1 Data for ProTmune Graft in GvHD Prophylaxis at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Therapeutics Receives IND Clearance from FDA for FT500, Off-the-Shelf NK Cell Product
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 50.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Therapeutics Presents Updates for Programs at SITC 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UPDATED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 50.00